ScreenPro Announces Insider Purchases of Shares

ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) ("ScreenPro" or the "Company") is pleased to report that certain members of the Board of Directors and Senior Management have purchased 2,841,600 shares of the Company between March 29, 2022, to March 31, 2022, in open-market transactions. Details of the purchase is as follows:

Michael Yeung, Chairman, purchased 660,000 shares at an average price of $0.075

Lena Kozovski, CEO, purchased 681,600 shares at an average price of $0.073

Paul Haber, CFO, purchased 800,000 shares at an average price of $0.062

Youngcho Lee, Director, purchased 700,000 shares at an average price of $0.070

"Our shareholders and the future of this company have the utmost importance to us. We believe in our mission for the future of ScreenPro and how it will continue to serve our community as the business evolves post pandemic. Health screening and keeping people safe and informed about their health is our priority. I'd like to personally thank our investors, board, and our team members as we continue to grow the company and add more value for our shareholders," said Lena Kozovski, CEO of the Company.

About ScreenPro

ScreenPro is a Screening and Medical Technology company that provides turnkey screening solutions with its proprietary medical alerting software. ScreenPro's unique access to multiple manufacturers of high-quality test kits and its strategic partnership with labs in British Columbia, Ontario and Quebec allows ScreenPro to be a full-service nationwide provider of COVID testing and breast cancer screening solutions across Canada. In addition, ScreenPro has its own medical doctor and nursing professionals with on the ground support staff and transportation, with access to high quality PPEs to ensure that clients are protected in all aspects of their testing needs.

For additional information on ScreenPro and other corporate information, please visit the Company's website at www.screenprosecurity.com

About Add Biomedical

ScreenPro's wholly owned subsidiary, Add Biomedical, is a biomedical screening company specialized in creating solutions for disease diagnosis. ScreenPro has exclusively purchased the Canadian entity of AddBiomedtiek Co, Korea, which gives the Company exclusive rights to their products within the North American marketplace. Acquiring Add Biomedical gives the Company access to a library of products. Currently, the Company has an interest to bring the CA 15-3 Rapid Test Kit's for breast cancer screening into the North American marketplace as well as Veterinary Animal Disease and Infectious Disease screening tests. The technology is easy to use, fast, portable, cost effective and can be operated in resource limited areas. Add Biomedical is committed to early diagnosis which can saves lives.

For additional information on Add Biomedical and other corporate information, please visit the Company's website at: www.addbiomedical.com

For more information about the Company, please refer to the Company's profile on SEDAR at www.sedar.com.

Neither the Canadian Securities Exchange (the "CSE") nor it's Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For further information please contact:

Lena Kozovski, CEO
Email: investors@screenprosecurity.com

Forward-Looking Statements:

Certain statements contained in this news release may constitute forward‐looking information, including statements relating to expectations regarding the acquisition and business of Concierge Medical Consultants Inc. and the future development of ScreenPro's business. Forward‐looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward‐looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward‐looking information. The actual results of ScreenPro could differ materially from those anticipated in this forward‐looking information as a result of regulatory decisions, competitive factors in the industries in which ScreenPro operates, prevailing economic conditions, changes to ScreenPro's strategic growth plans, and other factors, many of which are beyond the control of ScreenPro. Management of ScreenPro believes that the expectations reflected in the forward‐looking information herein are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward‐looking information should not be unduly relied upon. Any forward‐looking information contained in this news release represents ScreenPro's expectations as of the date hereof and is subject to change after such date. ScreenPro disclaims any intention or obligation to update or revise any forward‐looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

###

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/119011